VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8302
+0.0435 (+5.53%)
As of 12:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7867
Open0.8280
Bid0.8250 x 800
Ask0.8298 x 900
Day's Range0.8140 - 0.8800
52 Week Range0.3300 - 1.3800
Volume1,853,123
Avg. Volume1,130,617
Market Cap88.046M
Beta0.07
PE Ratio (TTM)N/A
EPS (TTM)-0.2900
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • Vivus Stock Rose 60% Last Week
    Market Realist4 hours ago

    Vivus Stock Rose 60% Last Week

    Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.

  • ACCESSWIRE4 hours ago

    Biotech CEO Presents: Merck’s $500M Pain, Our Potential Gain

    Synergy Pharma's valuation peaked after data suggested its CIC treatment could challenge Ironwood's Lizness; Vivus soared on potential to beat weight-loss drugs with significant adverse effects Bellus ...

  • ACCESSWIRE5 days ago

    Today’s Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Eleven Biotherapeutics and VIVUS, Inc. were two biotech stocks to see big gains in Wednesday's trading session. VIVUS reported first quarter earnings earlier this month and recently announced an agreement to acquire all rights to Janssen's exocrine pancreatic insufficiency drug, pancreaze, in the United States and Canada. Janssen is a subsidiary of Johnson & Johnson.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Vivus Inc Earnings Call

  • VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
    Zacks12 days ago

    VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

    VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

  • Associated Press14 days ago

    Vivus: 1Q Earnings Snapshot

    The Campbell, California-based company said it had a loss of 10 cents per share. The biopharmaceutical company posted revenue of $11.9 million in the period. In the final minutes of trading on Tuesday, ...

  • GlobeNewswire14 days ago

    VIVUS Reports First Quarter 2018 Financial Results

    Company provides business update on PANCREAZE ® acquisition, new Athyrium debt line and new management. Company to host conference call today at 4:30pm ET. CAMPBELL, Calif., May 08, 2018-- VIVUS, Inc., ...

  • GlobeNewswire18 days ago

    VIVUS Announces Date of 2018 Annual Meeting

    Pursuant to Rule 14a‑8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), stockholders may present proper proposals for inclusion in the 2018 Proxy Statement and for consideration at the Company’s 2018 Annual Meeting.  To be eligible for inclusion in the 2018 Proxy Statement, a proposal must be received by the Company no later than May 21, 2018 and must otherwise comply with Rule 14a‑8. In addition, under the Company’s Amended and Restated Bylaws, as further amended, in order to nominate a director or bring any other business before the stockholders at the 2018 Annual Meeting that will not be included in the 2018 Proxy Statement, the proposal must be received by the Company’s Corporate Secretary on or between May 10, 2018 and June 9, 2018.

  • ACCESSWIRE19 days ago

    VIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts Review

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on VIVUS, Inc. (VVUS) is a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health. VIVUS has announced new management members and new initiatives over the past few trading days. On April 30, 2018 VVUS announced the addition of three executives to the Company's senior leadership team.

  • ACCESSWIRE19 days ago

    Blog Exposure - VIVUS to Acquire Janssen Pharma’s PANCREAZE(R) Capsules in the United States and Canada

    LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on VIVUS, Inc. (NASDAQ: VVUS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VVUS as the Company's latest news hit the wire. On May 01, 2018, the Company announced that it has inked an agreement to acquire all of the product rights for Janssen Pharmaceuticals, Inc.'s PANCREAZE® (pancrelipase) Delayed-Release Capsules in the United States and Canada, for approximately $135 million.

  • ACCESSWIRE20 days ago

    Today’s Research Reports on Stocks to Watch: Avinger and VIVUS

    NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Positive developments sent shares of both Avinger and VIVUS higher on Tuesday. Avinger announced that its next generationPantheris Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross International Symposium 2018. VIVUS announced that it has entered into a definitive agreement for the acquisition of PANCREAZE.

  • GlobeNewswire21 days ago

    VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE®

    CAMPBELL, Calif., May 01, 2018-- VIVUS, Inc., a biopharmaceutical company, today announced that it has entered into a definitive agreement to acquire all product rights for PANCREAZE ® Delayed-Release ...

  • GlobeNewswire21 days ago

    VIVUS Restructures Debt and Gains Access to New Capital

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company and Athyrium Capital Management L.P. (“Athyrium”), a specialized asset management company focused on investment opportunities in the global healthcare sector, today announced an agreement to restructure a portion of VIVUS’ corporate debt while raising new funds through the issuance of debt securities to investment funds managed by Athyrium.

  • Marketwired22 days ago

    VIVUS Strengthens Executive Leadership Team

    VIVUS,Inc. , a biopharmaceutical company, today announced the addition of three executives to the Company's senior leadership team. John Amos has joined as the Company's new Chief Executive Officer and ...

  • Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
    Market Realist26 days ago

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY (year-over-year) growth in local currency.

  • Marketwired27 days ago

    VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018

    VIVUS, Inc. today announced that it will report financial results and provide a business update for the first quarter of 2018 after the market close on Tuesday, May 8, 2018. The company will host a conference ...

  • Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?
    Zackslast month

    Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?

    VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Associated Press2 months ago

    Vivus reports 4Q loss

    On a per-share basis, the Campbell, California-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $11.9 million in the period. For the year, the company reported ...

  • Marketwired2 months ago

    VIVUS Reports Fourth Quarter 2017 Financial Results

    VIVUS,Inc. , a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS

    NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46, ...

  • Marketwired5 months ago

    VIVUS Announces Change in Leadership

    VIVUS, Inc. today announced that it has reached agreement with Seth H. Z. Fischer pursuant to which he will step down as chief executive officer and a member of the board of directors effective December ...

  • Capital Cube6 months ago

    ETFs with exposure to VIVUS, Inc. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 VIVUS Inc Earnings Call